# US 2020/0138708 A1 · Implants and constructs including hollow fibers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138708 A1
- Document ID: US20200138708A1
- Status: Published application
- Kind: A1
- Application number: 16/712,365
- Filed: 2019-12-12
- Published: 2020-05-07
- Earliest claimed: 2015-07-23
- Assignees: Novaflux Inc.
- Applicants: Novaflux, Inc
- Inventors: Mohamed E. LABIB; Stanislav S. DUKHIN; Peter MATERNA; Jeffrey C. ROBERTSON; Ching-Yue LAI; Yacoob TABANI
- Web page: https://patentgrep.com/patent/US20200138708A1

## CPC

- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61B 17/06166: {Sutures (suture materials A61L17/00; manufacture of artificial threads D01D; treatment of threads D06M)}
- A61C 15/041: {Dental floss (chemical aspects A61Q11/00)}
- A61F 2/0063: {Implantable repair or support meshes, e.g. hernia meshes}
- A61F 2/02: Prostheses implantable into the body
- A61F 13/00063: {comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic (drug delivery dressings A61K9/70; chemical aspect of the additives A61L15/00)}
- A61L 17/005: {containing a biologically active substance, e.g. a medicament or a biocide}
- A61L 31/04: Macromolecular materials
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61M 27/002: {Implant devices for drainage of body fluids from one part of the body to another (intraocular A61F9/00781; middle ear A61F11/202)}
- A61B 2017/00893: {pharmaceutically effective}
- A61F 2250/0068: the pharmaceutical product being in a reservoir
- A61L 2300/406: Antibiotics
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61C: DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE (non-driven toothbrushes A46B; {tongue scrapers A61B17/24;} preparations for dentistry A61K6/00; preparations for cleaning the teeth or mouth A61K8/00, A61Q11/00)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Hollow fiber drug delivery devices are described. Device can contain structural or solid fibers. Fabric can be formed by fibers being interwoven or joined to each other. All or some of the fibers can be resorbable. Fibers can be subdivided, by deformations or closure points, into numerous compartments that separately deliver drug. Deformations can be located at points of fiber intersection or joining. Different drug or drug formulation can be provided in different places. Fibers can be given appropriate surface treatments or coatings to achieve desired properties such as wetting of pores and surfaces. Different release characteristics in different directions can be achieved. The hollow fibers can contain solid particles of drug, and can contain gel. Possible applications include hernia meshes, pouches, sutures, catheters, wound dressings, stents, nerve regrowth guides, refillable/drainable devices, and devices that deliver drug to lymphatic flow.

## Claims

### Claim 1

An implantable device, the device comprising:
a plurality of nonmetallic hollow fibers having native-permeable walls, the walls having characteristics such that molecules of a drug of interest can pass through the walls while larger molecules cannot pass through the walls, the hollow fibers having respective fiber lumens, the hollow fibers having respective first ends and respective second ends opposite the first ends; and
a feeder member having a feeder internal lumen, wherein at the first ends, the fiber lumens are in fluid communication with the feeder lumen,
wherein the feeder internal lumen comprises a septum that is configured to self-seal after puncture such that the drug can be fed into the feeder lumen and hence into the fiber lumens,
wherein the hollow fibers or the hollow fibers and further fibers are interwoven or adhered to form a fabric construct.

### Claim 2 (depends on 1)

The device of claim 1, wherein the device comprises a manifold that is in fluid communication with multiple of the hollow fibers.

### Claim 3 (depends on 1)

The device of claim 1, further comprising
a draining member having an internal lumen, wherein the second ends of the hollow fibers are in fluid communication with the draining internal lumen,
wherein the draining internal lumen comprises a septum that is configured to self-seal after puncture such that the fluid can be drained from the draining lumen and hence from the fiber lumens.

### Claim 4 (depends on 3)

A kit comprising the device of claim 3, comprising a catheter comprising two lumens and configured to supply a first material to the fiber lumens via the feeder member and also remove a second material from the fiber lumens via the draining member, feeding and draining occurring through respective catheter lumens.

### Claim 5 (depends on 3)

A method of treating a patient comprising:
providing in a patient's body a device of claim 3; and
introducing a first flowable substance through the feeder septum and simultaneously withdrawing a second flowable substance through the draining septum.

### Claim 6 (depends on 1)

The device of claim 1, wherein the fiber lumens contain dry drug particles.

### Claim 7 (depends on 6)

The device of claim 6, wherein the drug particles are suspended in a gel or liquid that has a viscosity greater than 500 centiPoise.

### Claim 8 (depends on 6)

The device of claim 6, wherein drug particles have average diameter of about 0.1 to about 10 micrometers.

### Claim 9 (depends on 1)

The device of claim 1, wherein the fiber lumens contain at least one of a substance selected from the group consisting of: an antimicrobial; an antibiotic; an anti-biofilm drug; a chemotherapeutic drug; a growth factor, a substance to suppress fibrosis; an anesthetic; an analgesic; an anti-inflammatory; an immunosuppressant; an immune modulator; a chemotherapeutic agent; an anti-coagulant; an anti-adhesion drug; a muscle relaxant; a tissue relaxant; and a biologic, and peptides, proteins, enzymes, antibodies, DNA, RNA, growth factors or modulators, immunogens, immune-therapeutics or the like, and any substance such as a chemical that can act on a cell, virus, tissue, organ or organism to create a change in functioning of the cell, virus, organ or organism to achieve a pharmaceutical or therapeutic effect.

### Claim 10 (depends on 1)

The device of claim 1, wherein the fabric construct comprises solid fibers that are intertwined with or interspersed with or attached to the hollow fibers.

### Claim 11 (depends on 1)

The device of claim 1, further comprising an osmogen contained inside the device, the osmogen being in a dry condition, the osmogen being capable of absorbing liquid and swelling and urging material to pass through the walls out of the device, wherein the material can pass through the wall and the osmogen has a molecular weight such that the osmogen is unable to pass through the wall.

### Claim 12 (depends on 1)

The device of claim 1, wherein the device or a portion thereof is resorbable.

### Claim 13 (depends on 1)

The device of claim 1,
wherein the device comprises a resorbable connector joining the feeder member to a remainder of the device, and
wherein when the resorbable connector is resorbed, the feeder member becomes disconnected from the remainder of the device.

### Claim 14 (depends on 1)

The device of claim 1, wherein the fabric construct is configured to substantially surround an area of tissue to be treated, a nerve, a blood vessel, a lymph duct, a lymph node, organ or implant.

### Claim 15 (depends on 1)

The device of claim 1, further comprising a second plurality of second nonmetallic hollow fibers having second native-permeable walls, the second native-permeable walls having characteristics such that molecules of a second drug of interest, which can be the same as the first, can pass through the second native-permeable walls while larger molecules cannot pass through the second native-permeable walls, the second fibers having respective second fiber lumens containing the second drug.

### Claim 16 (depends on 1)

The device of claim 1, wherein the fabric comprises connecting elements or fibers interwoven among the hollow fibers or adhered to the hollow fiber, the connecting elements or fibers being resorbable.

### Claim 17 (depends on 15)

A method of treating a patient comprising:
residing in the patient's body a device of claim 15 for a period of time effective to deliver the drug and for the connecting elements or fibers to resorb at least in part; and
further comprising pulling on the hollow fibers such that they are drawn as linear fiber from the patient's body.

### Claim 18 (depends on 1)

A method of treating a patient comprising:
providing in the patient's body a device of claim 1; and
further comprising, prior to the implanting the device, cutting an outer perimeter of the fabric construct to a desired shape and cauterizing cut ends of the hollow fibers formed by the cutting.

### Claim 19 (depends on 1)

A method of treating a patient comprising:
providing in the patient's body a device of claim 1; and
penetrating the patient's skin and penetrating the feeder septum to introduce a first flowable substance into the device.

### Claim 20 (depends on 18)

The method of claim 18, further comprising thereafter so introducing a second flowable substance in the device.

### Claim 21 (depends on 1)

A method of non-systematically delivering the drug to a patient comprising:
providing the fabric construct of claim 1 in a patient configured to deliver the drug to a tissue to be treated, a nerve, a blood vessel, a lymph duct, a lymph node, organ; and
periodically delivering the drug to the device via the septum.

### Claim 22 (depends on 21)

A method of treating or ameliorating a condition comprising applying the method of claim 21 by having the fabric construct configured to:
for metastatic cancer, provide the device configured for drug delivery to one or more lymph nodes at or near the site of a primary cancer and periodically delivering one or more chemotherapy drugs to the device; or
for pain, provide the device configured for drug delivery at or near a site of pain and periodically delivering one or more one or more anti-inflammatory agents, analgesics, or pain medications to the device; or
of infection, provide the device configured for drug delivery at or near tissue identified as a reservoir of infection and periodically delivering one or more one or more antimicrobial agents, antiseptic agents, antibiotics or antivirals to the device.
